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Abstract  
 
There is a pressing need for better pharmacological treatment strategies for psychiatric disorders 
as current treatment often results in partial symptom remission and unwanted side effects. A point 
of entry may be the glutamatergic system since glutamatergic dysregulation contributes to multiple 
psychiatric disorders. We evaluated the evidence from randomized controlled trials (RCTs) 
regarding the use of the glutamatergic drug riluzole in mental illnesses; and conducted preliminary 
meta-analyses of its effectiveness in treating obsessive-compulsive disorder (OCD) and 
depression. 
A systematic search was performed using PubMed (Medline), Embase, Cochrane Database of 
Systematic Reviews and PsycINFO. Meta-analyses were performed using Comprehensive Meta-
Analysis software.  
Twenty-three RCTs were included for qualitative analysis and showed positive effects of 
adjunctive/monotherapy riluzole in patients with OCD, depression, autism, substance abuse and 
schizophrenia. Seven studies were also used for quantitative analysis, which revealed positive but 
non-significant effects on OCD and depression. Riluzole was generally well tolerated  with few 
serious adverse events. 
The studies included in this systematic review were highly heterogeneous and the number of 
studies was limited per diagnostic condition. Moreover, few studies have examined riluzole as a 
single treatment. We suggest carrying out further work to provide definitive evidence for the 
benefit of riluzole in psychiatric illness.   
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1. Introduction 
Riluzole is an antiglutamatergic agent that is approved for the treatment of amyotrophic lateral 
sclerosis (ALS) (Miller et al., 2012). Chemically, riluzole is a benzothiazole that has antiepileptic 
(Benavides et al., 1985) and neuroprotective properties and a favorable side effect profile (Liboux 
et al., 1999). Riluzole primarily modulates the glutamatergic system, a system that is increasingly 
linked with the pathology of mood, anxiety and psychotic disorders. Riluzole is assumed to act by 
inhibiting voltage-gated sodium channels,  thereby reducing neurotransmitter release, and to 
enhance astrocytic uptake of extracellular glutamate (Pittenger et al., 2008). In vitro, these effects 
are mediated by processes linked to the n-methyl-D-aspartate (NMDA) receptor (Doble, 1996). 
Additionally, riluzole interacts with inhibitory neurotransmitters, increasing the depolarizing 
effect of GABA and thereby enhancing GABAergic inhibitory function (He et al., 2002; 
Mohammadi et al., 2001). Riluzole may exert its glutamate inhibiting effects also by increasing 
glutamate reuptake via glia cells (dos Santos Frizzo et al., 2004). In vitro, riluzole is also shown to 
attenuate release of acetylcholine and dopamine (Jahn et al., 2008; Jehle et al., 2000). These effects 
may be achieved at low riluzole concentrations (Urbani and Belluzzi, 2000). Riluzole is thus 
thought to reduce neuronal excitability and possibly increase neuroprotection through several 
mechanisms. Previous systematic reviews have assessed the pharmacological effects of riluzole 
and revealed promising initial trials in psychiatric disorders. At that time however, randomized 
controlled trials were lacking (Grant et al., 2010; Pittenger et al., 2008; Zarate Jr and Manji, 2008). 
Here, we provide an updated and comprehensive systematic review investigating the efficacy and 
tolerability of riluzole in the treatment of psychiatric disorders. In addition, we quantitatively 
examine its effects on depressive and obsessive-compulsive symptoms. 
2. Methods 
2.1. Literature search 
This review was performed according to the Preferred Reporting for Systematic Reviews and 
Meta-analysis (PRISMA) Statement (Moher et al., 2015). The literature search was conducted by 
two independent researchers (J.B. & M.H.) using PubMed (Medline), Embase, Cochrane Database 
of Systematic Reviews, and PsychINFO. Combinations of the following search terms were used: 
“riluzole”, “Rilutek” and “psychiatric”, “mental disorder”. The search had no year and language 
restrictions. See Supplementary Table 1 (Table S1) for an example search string. The search cut-
off date was February 19th, 2019. Reference lists of the included studies were searched for cross-
references. After independent screening was performed by J.B. and M.H., consensus about the 
included studies was reached between J.B., M.H. and J.Z.  
 
2.2. Inclusion criteria 
Articles were included when the following inclusion criteria were met: 1) randomized, double-
blind placebo-controlled trials that assessed the effect of riluzole; 2) the included patients were 
diagnosed with a psychiatric disorder, according to the diagnostic criteria of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, DSM-5) 
(Association, 2013; Frances, 1994), or the International Classification of Diseases (ICD-9 or ICD-
10); 3) studies were published in a peer-reviewed journal or conference book.  Risk of bias was 
assessed independently by J.B. and M.P. using the Cochrane Risk of Bias tool for randomized 
controlled trials (Table S2) (Higgins et al., 2011). 
 
2.3. Outcome measures 
2.3.1. Qualitative synthesis 
The efficacy of riluzole compared to placebo on symptoms of a psychiatric disorders were regarded 
the primary outcome measure. Additionally, adverse effects of the included studies are reported.  
 
2.3.2. Quantitative synthesis  
The primary outcome measures were depressive symptoms in patients with major depressive 
disorder (MDD) and obsessive-compulsive symptoms in patients with obsessive-compulsive 
disorder (OCD). Depressive symptoms were measured with the Montgomery-Asberg Depression 
Rating Scale (MADRS) (Montgomery and Asberg, 1979) or the Hamilton Rating Scale for 
Depression (HAM-D) (Hamilton, 1986). In case multiple rating scales were used, preference was 
given to the MADRS or HAM-D. Obsessive-compulsive symptoms were measured with the 
(Children’s) Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (Goodman et al., 1989a, 1989b; 
Scahill et al., 1997), of which total and subscale scores were used.  
 
2.4. Statistics 
Comprehensive Meta-Analysis (CMA) software version 2.0 was used to perform all analyses, 
using a random-effects model (Borenstein et al., 2005). For every individual study, Hedges’ g was 
calculated for each outcome measure. To obtain this effect size, per treatment arm, mean 
differences in change scores (end of treatment minus baseline) and standard deviations (SD)) or 
pre- and post-means (+SD) were used. To avoid overestimation of the true effect sizes caused by 
the pre-post treatment correlation (Dunlap et al., 1996), change scores were preferred. When these 
values were not reported, we used exact F-, t- or p-values. All effect sizes were calculated twice 
independently from the original articles to check for errors.   
Studies were combined in meta-analyses to calculate a mean weighted effect size for each 
outcome measure, using a random-effects model. To investigate whether studies could be taken 
together to share a common population effect size, the Q-value and I2-statistic were evaluated for 
each analysis. The Q-statistic tests the existence of heterogeneity, and displays a chi-square 
distribution with k-1 degrees of freedom (k=number of studies), where Q-values higher than the 
degrees of freedom indicate significant between-studies variability. I2 reflects which proportion of 
the observed variance reflects differences in true effect sizes, rather than sampling error, ranging 
from 0 to 100%. Values of 25%, 50%, and 75% can be interpreted as low, moderate, and high, 
respectively (Higgins et al., 2003).  
Additionally, funnel plots were inspected for asymmetry in order to check for publication 
bias. Potential asymmetry was tested with Egger’s test, using a significance level of α = .05 (2-
tailed). Effect sizes with a p-value smaller than .05 were considered statistically significant. Effect 
sizes were interpreted according to the guidelines by Cohen, with an effect size of .20 indicating a 
small effect, .50 a medium and over .80 a large effect (Cohen, 1988).  
 
3. Results 
A flow diagram of the literature search is depicted Figure 1. After screening on title and abstract, 
the search yielded 24 articles. After full-text reading 23 articles, describing 20 trials on riluzole 
use in psychiatric disorders remained, which are described in Table 1 (Ajram et al., 2015; Ciraulo 
et al., 2005; Emamzadehfard et al., 2016; Farahzadi et al., 2018; Farokhnia et al., 2014; Ghaleiha 
et al., 2013; Grant et al., 2014; Ibrahim et al., 2012; Joseph et al., 2011; Lemmon et al., 2015; 
Mathew et al., 2015, 2017, 2010; Niciu et al., 2014; Nicolson et al., 2017; Park et al., 2017; 
Pittenger et al., 2015; Salardini et al., 2016; Vingerhoets et al., 2018; Wilkinson et al., 2018, 2016; 
Wink et al., 2018; Zarate, 2011). Seven studies were included in the meta-analyses (see Table 2 
for descriptive information). One study used a cross-over design, only the outcomes of the first six 
weeks were included in the analyses (Mathew et al., 2017). Taken these studies together, the 
efficacy of riluzole versus placebo was quantitatively assessed in a total of 451 patients.  
 
3.1. Qualitative synthesis 
Depressive disorders 
Eight studies investigated riluzole in patients with depressive disorders, including MDD and 
bipolar depression (BD) (Ibrahim et al., 2012; Mathew et al., 2015, 2017, 2010; Niciu et al., 2014; 
Park et al., 2017; Salardini et al., 2016; Wilkinson et al., 2018, 2016). One study, described in two 
articles, focused on Brain Derived Neurotrophic Factor in plasma (pBDNF) and serum (sBDNF) 
and reported lower pBDNF and sBDNF levels at baseline in responders to riluzole (Wilkinson et 
al., 2018, 2016). The remaining six trials investigated reduction of depressive symptoms as 
primary outcome, measured by MADRS and HAM-D scores. Three of these studies used a design 
investigating post-ketamine relapse and potential effects of riluzole on relapse prevention after 
ketamine infusion or ketamine non-responders (Ibrahim et al., 2012; Mathew et al., 2010; Niciu et 
al., 2014). One study investigated efficacy of riluzole as monotherapy for depression (Park et al., 
2017). The efficacy of riluzole on depressive symptoms is also included in the quantitative 
assessment.  
 
Obsessive-compulsive disorders  
Of the included articles, five publications analyzed disorders related with obsessive-compulsive 
behavior (Emamzadehfard et al., 2016; Grant et al., 2014; Joseph et al., 2011; Lemmon et al., 2015; 
Pittenger et al., 2015) summarized as OCD. One small trial was done in children with Tourette 
Syndrome and examined the effect of riluzole on tics (Lemmon et al., 2015). Riluzole showed no 
superior effect compared to placebo in reducing tic-related behavior. Efficacy of riluzole on 
obsessive-compulsive symptoms is also summarized in the quantitative analyses.  
 
Autism spectrum disorders   
Three studies examined efficacy of riluzole in autism spectrum disorders (ASD) (Ghaleiha et al., 
2013; Nicolson et al., 2017; Wink et al., 2018). Long-term adjunct treatment (10-12 weeks) in 
young children with ASD resulted in a significant effect on irritability (Ghaleiha et al., 2013) and 
long-term monotherapy resulted in reduction of irritability and hyperactivity (Nicolson et al., 
2017). However, in another sample of children and young adults (age 12-25 years), no such effect 
was found (Wink et al., 2018). 
 
Other psychiatric disorders including psychosis spectrum disorders  
Two studies investigated efficacy of riluzole on symptoms related to substance abuse (Ciraulo et 
al., 2005; Farahzadi et al., 2018). Methamphetamine dependent patients responded positively on 
riluzole monotherapy with respect to severity of dependence, withdrawal, craving and depressive 
symptoms (Farahzadi et al., 2018), while in cocaine dependent patients no effect was found when 
riluzole was given in combination with cognitive behavioral therapy (Ciraulo et al., 2005). The 
only randomized controlled trial to date with riluzole in schizophrenia (Farokhnia et al., 2014) 
investigated effects of riluzole augmentation of risperidone on positive and negative symptoms in 
patients with schizophrenia and reported significant positive effects of riluzole on negative 
symptoms after 12 weeks of treatment.  
 Single dose challenge studies 
A single dose study in patients with 22q11-Deletion Syndrome (22q11DS) found higher baseline 
glutamate levels in 22q11DS patients compared to controls and a decrease in glutamate 
concentrations after riluzole challenge (Vingerhoets et al., 2018). In MDD one study provided a 
single dose of riluzole and found that the mood effects after 230 minutes correlated with slow 
wave parameters on electroencephalogram (Zarate, 2011). In ASD, one single-dose study 
investigated effects on measures of glutamate and GABA in the brain using MR-spectroscopy 
(Ajram et al., 2015). Riluzole increased the relative proportion of GABA in the prefrontal cortex 
of the ASD group but not in the control group. In addition, exposure to a single dose of riluzole 
did not alter the functional connectivity of the prefrontal lobe in controls but ‘restored’ functional 
connectivity in the ASD group to a level comparable with the control baseline (Ajram et al., 2015). 
 
3.2. Quantitative synthesis 
Results for depressive symptoms and obsessive-compulsive symptoms are depicted in Figure 2 
and Table 3. Small non-significant effect sizes were found for depressive symptoms and for Y-
BOCS total, as well as the obsession and compulsion subscales of the Y-BOCS (see also Figure 
S1 and S2). Meta-regression showed that age, treatment duration and dosage were not related to 
effect sizes found in the studies (all p>.1). Heterogeneity was high for all outcome measures, see 
Table 2. Egger’s tests were not significant for any outcome measure.  
 
3.3. Safety and tolerability  
Adverse effects are reported in Table S3. Twenty-two out of the twenty-three included publications 
reported on experienced side effects. Only three studies reported serious adverse events, including 
one case of acute pancreatitis (Grant et al., 2014), one case of dyspnea (Farahzadi et al., 2018) and 
one case of severe nausea (Farahzadi et al., 2018; Niciu et al., 2014). Most studies reported no 
difference in frequency of adverse events between the riluzole and placebo arm (see Table S3). 
Two studies found significantly more side-effects in the riluzole group, including nausea (n=8) 
(Lemmon et al., 2015; Pittenger et al., 2015), poor coordination (n=3) (Pittenger et al., 2015), and 
increased appetite (n=12) (Ghaleiha et al., 2013). Increased transaminases were reported in a total 
of seven patients.  
 
4. Discussion 
This study provides a systematic overview of current literature regarding efficacy of riluzole for 
psychiatric disorders.  
Qualitative assessments of the studies included in the systematic review suggested some 
positive effects of riluzole on symptoms of ASD, substance abuse and psychosis spectrum 
disorders. Moreover, on a biological level, riluzole has been shown to decrease glutamate 
concentrations in 22q11DS. Because for each of these disorders, few RCTs were available, 
replication studies are needed to see whether these effects are robust.  
In the quantitative analyses, seven studies were included that all compared riluzole to 
placebo in a double blind randomized controlled design. We found small, non-significant positive 
effects of riluzole on depressive and obsessive-compulsive symptoms. Age of the patient, dosage 
and treatment duration did not influence these effects. However, the number of studies that could 
be included in the quantitative analyses was limited, as a consequence, our meta-analytical 
estimates are affected by high uncertainty and should be considered as a preliminary synthesis of 
the available literature.  
The greatest strength of the present study is that it provides an up-to-date, quantitative and 
qualitative overview of the literature regarding the efficacy of riluzole in psychiatric disorders. 
Though our results reveal no significant overall effects of riluzole, given the small number of 
studies that could be included in the quantitative analyses, our results do not exclude the possibility 
that in some cases riluzole can improve depressive or obsessive-compulsive symptoms. 
Furthermore, most studies assessed the use of riluzole as an augmentation strategy, while only a 
few trials assessed its use as monotherapy (Farahzadi et al., 2018; Lemmon et al., 2015; Park et 
al., 2017). Given that in the augmentation studies most patients required continued 
pharmacological treatment, it is likely that relatively ill patients were included in these trials, 
possibly even therapy-resistant patients who had not responded to first- or second- line treatment. 
Indeed, preliminary evidence suggests that riluzole may have a role in treatment-resistant 
schizophrenia (Pillinger et al., 2019). Whether modulation of the glutamate system (for example 
by riluzole) may be beneficial in early stages of psychiatric disorders has never been investigated. 
For ALS, riluzole has proven to be particularly effective both early and late in the disease (de 
Jongh et al., 2019). Thus, however, more research is required to prove its efficacy as a single 
treatment strategy, possibly at early disease stages. 
Our knowledge of the role of the glutamate/GABA system in etiology of psychiatric 
disorders has advanced enormously over the past decades. This understanding allows for discovery 
of novel therapeutic strategies. A good example is the glutamate-enhancing drug ketamine, which 
is now recognized as an effective antidepressant (Murrough, 2016; Schwartz et al., 2016). There 
is mounting evidence that altered balance between inhibition and excitation, or 
glutamatergic/GABA dysregulation, is involved not only in depression (McNally et al., 2008; 
Müller and Schwarz, 2007), but also in anxiety disorders (Bergink et al., 2004; Swanson et al., 
2005), ASD (Ghanizadeh, 2013; Mariani et al., 2015; Penn, 2006; Ratajczak, 2011) and psychosis 
spectrum disorders (Hu et al., 2015; Poels et al., 2014; Uno and Coyle, 2019).  
In our systematic review two out of the three studies reported positive effects of riluzole 
on irritability in ASD (Ghaleiha et al., 2013; Nicolson et al., 2017). At present, irritability in the 
context of ASD is treated with antipsychotics (NICE Clinical Guidelines, 2013). However, the use 
of antipsychotics in children and young people is associated with increased mortality (Ray et al., 
2019). In this context, it may be worthwhile to further investigate the efficacy of riluzole for 
irritability in ASD (and related conditions) to examine whether riluzole has a better risk-/benefit 
balance than antipsychotics.  
Riluzole may also be relevant as an augmentation strategy in psychotic disorders. A recent 
pharmacological challenge study in treatment-resistant schizophrenia patients showed a decrease 
in glutamate + glutamine (GLX) concentrations in the anterior cingulate cortex (ACC) after a 2-
day riluzole challenge (Pillinger et al., 2019). In this study, higher baseline GLX concentrations 
were associated with more severe negative symptoms and worse verbal learning. Because the study 
used a non-randomized, non-blinded design, it was not included in the current systematic review. 
Hopefully, in the near future more information will become available on effects of 
extended riluzole treatment in psychiatric disorders. This may inform whether riluzole is a useful 
augmentation or monotherapy strategy. In addition, pharmacological challenge studies using 
riluzole (Ajram, 2015; Vingerhoets et al., 2018) may increase our understanding of the 
glutamate/GABA system and its role in the pathophysiology of psychiatric disorders. 
In conclusion, riluzole augmentation may be a useful pharmacological strategy for a variety 
of psychiatric disorders. Riluzole may have some positive effects on symptoms related to psychotic 
disorders, substance abuse disorders,  depression and OCD, and is reasonably well-tolerated. 
However, existing RCTs on riluzole are heterogeneous and only a limited number of studies is 
available for each psychiatric disorder. The results of the meta-analysis show no overall significant 
effect of riluzole on depressive and obsessive-compulsive symptoms. Future studies will need to 
establish whether there is a role for riluzole in the treatment of psychiatric disorders.  
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Figure legends 
 
 Figure 1: Flow diagram of the search 
 
Figure 2: Meta-analysis of the effect of riluzole on depressive symptom severity (A) and 
obsessive-compulsive symptom severity (B).  
 
Highlights 
• Twenty-three randomized-controlled trials were included for qualitative analysis 
• Several studies reported positive effects of riluzole on symptoms of various psychiatric 
disorders 
• Preliminary meta-analyses did not reveal significant effects 
• Riluzole was generally well tolerated with few serious side effects 
• Further studies are needed to confirm a potential of riluzole in the treatment of mental 
illnesses 
 
Supplementary material  
Table S1:  Systematic search strategy  
PUBMED 
#1: Domain 
"mental disorder"[Title/Abstract] OR "mental disease"[Title/Abstract] OR mental 
ill*[Title/Abstract] OR "mentally ill"[Title/Abstract] OR "mental sickness"[Title/Abstract] 
OR "mentally sick"[Title/Abstract] OR psychiatric*[Title/Abstract] OR 
psychiatry[Title/Abstract] OR "psychological disorder"[Title/Abstract] OR "psychological 
disease"[Title/Abstract] OR "anxiety"[Title/Abstract] OR "panic"[Title/Abstract] OR 
"phobic disorder"[Title/Abstract] OR *phobia[Title/Abstract] OR "PTSD"[Title/Abstract] 
OR "PTSS"[Title/Abstract] OR "posttraumatic stress"[Title/Abstract] OR "post traumatic 
stress"[Title/Abstract] OR "OCD"[Title/Abstract] OR "obsessive 
compulsive"[Title/Abstract] OR "mood disorder"[Title/Abstract] OR 
depressed[Title/Abstract] OR bipolar[Title/Abstract] OR mania[Title/Abstract] OR 
manic[Title/Abstract] OR depression[Title/Abstract] OR depressive [Title/Abstract] OR 
schizofrenia[Title/Abstract] OR schizophrenia[Title/Abstract] OR 
schizoaffective[Title/Abstract] OR schizo-affective[Title/Abstract] OR 
schizophrenic*[Title/Abstract] OR schizophreniform[Title/Abstract] OR 
schizoform[Title/Abstract] OR psychotic*[Title/Abstract] OR psychosis[Title/Abstract] OR 
psychoses[Title/Abstract] OR "dissociative disorder"[Title/Abstract] OR "dissociative 
identity"[Title/Abstract] OR "personality disorder"[Title/Abstract] OR 
autism[Title/Abstract] OR autistic*[Title/Abstract] OR "ADHD"[Title/Abstract] OR 
"attention deficit"[Title/Abstract] OR "eating disorder"[Title/Abstract] OR "anorexia 
nervosa"[Title/Abstract] OR "bulimia"[Title/Abstract] OR "feeding 
disorder"[Title/Abstract] OR "substance disorder"[Title/Abstract})) OR "Mental 
Disorders"[Mesh] 
#2: Determinant 
"Riluzole"[Title/Abstract] OR "Riluzol"[Title/Abstract] OR "Rilutek"[Title/Abstract] OR 
"Teglutik"[Title/Abstract] OR "Tiglutik"[Title/Abstract] OR Glentek[Title/Abstract] OR 
"Riluzole"[Mesh] 
#3: #1 AND #2 
 
 
 
 
Table S2 Risk of bias assessment 
Study 
Random 
allocation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Double 
blind 
setting 
(performa
nce bias) 
Blinding of 
outcome 
assessment 
(detection 
bias) 
Incomplete 
outcome data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) Funding 
Ajram et al. (2015) + + + U + + U 
Ciraulo et al. (2005) + - - + - + + 
Emamzadehfard et al. (2016) + + + + + + + 
Farahzadi et al. (2018) + + + + + + + 
Farokhnia et al. (2014)  + + + + + + + 
Ghaleiha et al. (2013) + + + + + + + 
Grant et al. (2014) & Joseph et al. 
(2011) 
+ + U U + + - 
Ibrahim et al. (2012) + + + + - - + 
Lemmon et al. (2015) + + + + + + + 
Mathew et al. (2010) + + + + + + - 
Mathew et al. (2015, 2017)  + + + + + + + 
Niciu et al. (2014)  + + + + + + + 
Nicolson et al. (2017) + + + + U U U 
Park et al. (2017)  + U U U - - + 
Pittenger et al. (2015)  + + + + + + + 
Salardini et al. (2016) + + + + + + + 
Vingerhoets et al. (2018) n.a.  n.a.  + + + + U 
Wilkinson et al. (2016, 2018) + + + + + + + 
Wink et al. (2018) + + + + + + + 
Zarate et al. (2011) U U U U - + + 
Table Legend: + = low risk of bias, - = high risk of bias, U = unclear risk of bias, n.a. = not applicable.  
 
Table S3: Overview reported adverse events 
 
  
Study Serious Adverse Events 
(N) 
Common Adverse Events Transaminases/blood count 
differences (N) 
Ciraulo et al (2005) None Not reported Not reported 
Emamzadehfard et al (2016) None No significant difference Increased transaminases (1) 
Farahzadi et al (2018) Dyspnea (1) Severe 
nausea/diarrhea (1) 
No significant difference Highly increased transaminases (1) 
Farokhnia et al (2014) None No significant difference Not reported 
Ghaleiha et al (2013) None Weight gain and increased appetite No significant difference 
Grant et al (2014) Pancreatitis (1) No significant difference Slightly increased transaminases (5) 
Ibrahim et al (2012) None No significant difference No significant difference 
Lemmon et al (2015) None Gastrointestinal upset, fatigue, 
diarrhea , light-headedness and 
irritability 
Not reported 
Mathew  et al (2010) None No significant difference No significant difference 
Mathew  et al (2017) None Headache, fatigue and body pain No significant difference 
Niciu  et al (2014) Severe nausea (1) Not reported Not reported 
Nicolson et al. (2017) None Not reported Not reported 
Park et al (2017) Not reported Not reported Decreased hematocrit (1),  
Elevated creatinine (1) 
Pittenger  et al (2015) None Nausea and poor coordination No significant results 
Salardini et al (2016) None No significant difference No significant difference 
Wilkinson  et al (2018) Not reported Not reported Not reported 
Wink et al (2018) None No significant difference No significant difference  
Table legend: Reported differences in bold. 
Figure S1 and S2. Meta-analysis of the effect of riluzole on obsessive and compulsive symptoms, as measured with Y-BOCS.  
Study name Outcome Diagnosis Hedges's g and 95% CI
Hedges's 
g p-Value
Ememzadehfard et al. (2016) Y-BOCS compulsion OCD 0,623 0,029
Grant et al. (2014) Y-BOCS compulsion OCD + ASD -0,130 0,642
Pittenger et al. (2015) Y-BOCS compulsion OCD -0,100 0,757
0,144 0,395
-1,00 -0,50 0,00 0,50 1,00
Favours A Favours B
Meta Analysis
Study name Outcome Diagnosis Hedges's g and 95% CI
Hedges's 
g p-Value
Ememzadehfard et al. (2016) Y-BOCS obsession OCD 0,453 0,108
Grant et al. (2014) Y-BOCS obsession OCD + ASD -0,084 0,764
Pittenger et al. (2015) Y-BOCS obsession OCD 0,151 0,639
0,173 0,305
-1,00 -0,50 0,00 0,50 1,00
Favours A Favours B
Meta Analysis
